Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


Cancer vax combo lands

Posted 19 November 2020

Clinical research organisation Novotech is gearing up to trial yet another genetically modified (GM) cancer vaccine in Australia as the Office of Gene Technology Regulator completes its risk assessment of the company's proposed GM bladder cancer vaccine study.

This week the Sydney-based company applied for a licence application to run a phase 1/2a clinical trial of Takeda's TBio-6517, a GM Vaccinia virus in combination with MSD's Keytruda as a treatment for patients with advanced solid cancerous tumours.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Picking the path out of Covid
Now is not the time for leaders to play it safe
Special Report
Aust Covid Vaccine Tracker
UPDATE: Gilead hits back at WHO over remdesivir
Approvals Action
Trio of new drugs on ARTG
Roche, Seqirus, Clinuvel enlarge local portfolios